. 2023 Aug 2;10:1225654. doi: 10.3389/fcvm.2023.1225654

Table 5.

Lung function tests: change from baseline in FEV₁, FVC, and FEF_25%–75% in patients with moderate or severe COPD following administration of Lumason®.

	Change from baseline post-injection at:	Lumason®—Placebo
	Change from baseline post-injection at:	Mean	SD	95% CI^b
FEV₁(ml)	1 min	1.9	193.54	−121.1, 124.9
	3 min	25.2	255.41	−137.1, 187.4
	9 min	−60.9	174.83	−172.0, 50.2
	10 min	−34.6	146.64	−127.8, 58.6
	11 min	−42.4	199.51	−169.2, 84.3
FVC (ml)	9 min	−103.7	278.22	−280.4, 73.1
	10 min	−73.9	265.94	−242.9, 95.1
	11 min	−97.0	359.80	−325.6, 131.6
FEF_25%–75% (L/s)	9 min	10.2	75.23	−37.6, 58.0
	10 min	5.6	125.44	−74.1, 85.3
	11 min	12.4	140.24	−76.7, 101.5

n = 12 for all assessments.

Taken from Reference (31).

FEV₁, indicates forced expiratory volume; FVC, forced vital capacity; FEF, forced mid-expiratory flow; CI, confidence interval.

^{^a}

Difference between Lumason® (SonoVue™) and placebo in the change from baseline in FEV₁, FVC, or FEF_25%–75%.

^{^b}

Based on a comparison between Lumason® (SonoVue™) and placebo in the change from baseline in FEV₁ by using a paired t-test.